Research Applications
Weight Loss and Fat Reduction
Clinical investigations demonstrate that cagrilintide produces substantial, dose-dependent reductions in body weight through multiple complementary mechanisms. In a pivotal Phase 2 dose-finding trial involving 706 participants without diabetes but with obesity or overweight plus comorbidities, cagrilintide monotherapy at doses ranging from 0.3 to 4.5 mg weekly resulted in weight reductions of 6.0% to 10.8% over 26 weeks compared to 3.0% with placebo. The highest dose of 4.5 mg produced significantly greater weight loss than the approved GLP-1 receptor agonist liraglutide 3.0 mg (10.8% vs 9.0%, treatment difference 1.8%, p=0.03).
The weight reduction effects of cagrilintide are mediated primarily through decreased caloric intake rather than increased energy expenditure. Research demonstrates that the peptide reduces total food consumption by enhancing satiety signals and promoting earlier meal termination. Metabolic analyses reveal that cagrilintide treatment leads to preferential loss of fat mass while preserving lean body tissue to a greater degree than many weight loss interventions. In DXA scan analyses from the REDEFINE 1 trial, 66.9% of weight loss with cagrilintide-semaglutide combination therapy was attributable to fat mass loss, with only 33.1% from lean soft tissue—a more favorable body composition change compared to 43.3% lean tissue loss observed with placebo. Among participants achieving ≥30% weight loss, body fat percentage decreased from 46.3% to 33.2% at 68 weeks, while lean soft tissue proportion increased from 51.3% to 63.2%.
Studies indicate that cagrilintide treatment produces significant reductions in waist circumference, a key marker of visceral adiposity and metabolic risk. The peptide's effects on reducing central obesity contribute to its broader cardiometabolic benefits, as visceral fat accumulation is strongly associated with insulin resistance, dyslipidemia, and cardiovascular disease. The sustained appetite suppression achieved with cagrilintide enables participants to maintain reduced caloric intake over extended treatment periods without the compensatory increase in hunger that often undermines weight loss efforts, representing a crucial advantage for long-term weight management.
Sources:
Glycemic Control and Metabolic Health
Cagrilintide demonstrates significant effects on glucose metabolism and glycemic regulation, particularly in individuals with type 2 diabetes. In a 32-week Phase 2 trial evaluating cagrilintide combined with semaglutide (CagriSema) in 92 participants with type 2 diabetes and obesity, the combination therapy achieved a mean HbA1c reduction of 2.2 percentage points from baseline, significantly superior to cagrilintide monotherapy (0.9 percentage point reduction) and numerically greater than semaglutide monotherapy (1.8 percentage point reduction). These improvements in glycemic control occurred alongside substantial weight loss, demonstrating the dual metabolic benefits of amylin receptor activation.
Continuous glucose monitoring data from this trial revealed marked improvements in glycemic variability and time in target range. Time in range (blood glucose 3.9-10.0 mmol/L) increased from 45.9% at baseline to 88.9% at week 32 with CagriSema treatment, compared to increases from 32.6% to 76.2% with semaglutide alone and 56.9% to 71.7% with cagrilintide alone. Fasting plasma glucose decreased by 3.3 mmol/L with CagriSema, significantly more than the 1.7 mmol/L reduction with cagrilintide monotherapy (p=0.0010). These effects on glycemic parameters reflect cagrilintide's multifaceted mechanisms including delayed gastric emptying that moderates postprandial glucose excursions, suppression of inappropriate glucagon secretion, and indirect enhancement of insulin sensitivity through weight loss and reduced lipotoxicity.
In the REDEFINE 2 trial involving adults with overweight/obesity and type 2 diabetes, 73.5% of participants treated with CagriSema achieved an HbA1c level of ≤6.5% compared to 15.9% with placebo, meeting stringent glycemic targets that reduce long-term diabetes complications. Among participants with prediabetes enrolled in REDEFINE 1, 87.7% achieved normoglycemia with CagriSema treatment, demonstrating the therapy's potential for diabetes prevention. The peptide's ability to improve insulin sensitivity is evidenced by reductions in insulin resistance markers and improvements in beta-cell function, suggesting disease-modifying effects beyond symptomatic glucose lowering.
Research indicates that cagrilintide's metabolic benefits extend to lipid metabolism, with treatment associated with favorable changes in lipid profiles including reductions in triglycerides and improvements in cholesterol parameters. The peptide's effects on reducing hepatic lipid accumulation and improving metabolic flexibility—the capacity to efficiently switch between carbohydrate and fat oxidation—contribute to comprehensive metabolic health improvements that address multiple pathophysiological defects underlying metabolic syndrome and type 2 diabetes.
Sources:
Appetite Regulation and Satiety Enhancement
The primary therapeutic mechanism of cagrilintide involves potent modulation of appetite-regulating neural circuits through direct actions on brainstem nuclei that process satiety signals. The peptide activates amylin receptors located in the area postrema and nucleus tractus solitarius, critically positioned brain regions that lack a complete blood-brain barrier and thus serve as chemosensory zones detecting circulating hormonal signals related to nutritional status. By binding to these receptors, cagrilintide initiates signaling cascades that communicate satiation to downstream appetite-controlling regions including the hypothalamic arcuate nucleus, ventral tegmental area, and laterodorsal tegmental nucleus.
Research demonstrates that cagrilintide's satiety-promoting effects operate through both homeostatic pathways (regulating energy balance and metabolic needs) and hedonic pathways (controlling reward-driven eating and food preferences). This dual action on appetite regulation distinguishes amylin analogs from interventions that target only one aspect of eating behavior. Clinical trial participants report enhanced feelings of fullness, reduced hunger between meals, and decreased cravings for high-calorie foods—effects that facilitate adherence to reduced-calorie dietary patterns without the psychological burden of constant hunger that often undermines weight loss attempts.
The peptide's action on gastric emptying represents a complementary mechanism supporting prolonged satiety. By delaying the rate at which food exits the stomach and enters the small intestine, cagrilintide extends the period of gastric distension and nutrient presence in the upper gastrointestinal tract, both of which contribute to fullness signaling through vagal afferent pathways. Studies measuring gastric emptying rates demonstrate significant delays with cagrilintide treatment, correlating with participants' subjective reports of increased meal-induced satiety and reduced voluntary food intake. This slowing of gastric motility occurs specifically in the postprandial state and is coordinated with the hormonal milieu following nutrient ingestion, ensuring that the effect enhances rather than disrupts normal digestive physiology.
The sustained duration of action conferred by cagrilintide's long half-life ensures consistent appetite suppression throughout the weekly dosing interval, avoiding the fluctuations in appetite control that can occur with short-acting agents. Preclinical studies demonstrate that while native amylin reduces food intake for only a few hours, a single dose of cagrilintide maintains appetite suppression for 48-60 hours in rodent models, with clinical pharmacokinetic data supporting similarly prolonged effects in humans. This pharmacological stability enables participants to maintain consistent eating patterns and avoid the rebound hunger that might occur with agents requiring more frequent dosing.
Sources:
Cardiometabolic Benefits and Cardiovascular Risk Reduction
Emerging evidence demonstrates that cagrilintide treatment produces significant improvements in multiple cardiovascular risk factors beyond its effects on weight and glucose control. In the REDEFINE 1 trial, participants receiving CagriSema (cagrilintide-semaglutide combination) experienced a mean reduction in systolic blood pressure of 10.9 mm Hg compared to 2.1 mm Hg with placebo at 68 weeks—a clinically meaningful improvement that substantially reduces cardiovascular disease risk. Diastolic blood pressure decreased by 5.3 mm Hg with CagriSema versus 1.4 mm Hg with placebo. Notably, 63% of participants in the CagriSema group achieved blood pressure targets compared to 32% with placebo, and among those with resistant hypertension, 42% reached target blood pressure with CagriSema versus 29.3% with placebo.
The blood pressure-lowering effects of cagrilintide-based therapy enabled substantial reductions in antihypertensive medication use: 39.6% of participants treated with CagriSema decreased or discontinued their blood pressure medications during the trial, compared to only 18.8% in the placebo group. These improvements in blood pressure occur through multiple mechanisms including weight loss, reduced sympathetic nervous system activity, improved endothelial function, and decreased fluid retention associated with metabolic dysfunction. The magnitude of blood pressure reduction observed with cagrilintide therapy approaches that achieved with dedicated antihypertensive medications, representing a significant cardiovascular protection benefit.
Lipid profile improvements constitute another important cardiometabolic benefit of cagrilintide treatment. Clinical trials demonstrate reductions in triglycerides, improvements in HDL cholesterol, and favorable changes in LDL cholesterol concentrations. These lipid modifications, combined with weight loss and improved glycemic control, address multiple components of the metabolic syndrome phenotype that confers elevated cardiovascular risk. Research also indicates reductions in inflammatory markers including C-reactive protein (CRP), IL-6, and TNF-α with cagrilintide therapy, reflecting decreased systemic inflammation that contributes to atherosclerosis and cardiovascular disease progression.
The potential for cagrilintide-based therapies to reduce major adverse cardiovascular events (MACE) is currently under investigation in dedicated cardiovascular outcomes trials. Given the established cardiovascular benefits of GLP-1 receptor agonists and the complementary mechanisms of amylin analogs, combination therapy with cagrilintide and semaglutide may provide synergistic cardiovascular protection. Preliminary data suggest improvements in subclinical cardiovascular markers and risk factors that predict long-term event reduction, positioning cagrilintide as a potentially transformative therapy not only for metabolic health but also for comprehensive cardiometabolic disease management.
Sources:
Synergistic Effects in Combination Therapy
The combination of cagrilintide with GLP-1 receptor agonists, particularly semaglutide, represents a paradigm shift in obesity and metabolic disease pharmacotherapy by simultaneously targeting complementary hormonal pathways. While GLP-1 receptor agonists primarily act through incretin-based mechanisms—stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying via GLP-1 receptors in the pancreas and brain—cagrilintide operates through distinct amylin and calcitonin receptor pathways that enhance satiety through different neural circuits. This dual-pathway approach produces additive and potentially synergistic effects that exceed what either agent achieves alone.
Clinical trial data demonstrate the superior efficacy of combination therapy across multiple outcomes. In Phase 1b studies, participants receiving cagrilintide doses of 1.2 or 2.4 mg combined with semaglutide 2.4 mg achieved 17.1% weight loss over 20 weeks, compared to 9.8% with semaglutide plus placebo—representing an absolute difference of 7.3 percentage points attributable to cagrilintide's addition. The Phase 3 REDEFINE 1 trial, enrolling 3,417 adults with obesity or overweight without diabetes, demonstrated that CagriSema produced mean weight loss of 20.4-22.7% at 68 weeks (depending on estimand) compared to 2.3-3.0% with placebo and 9.4% with semaglutide monotherapy. Remarkably, 53.6% of participants achieved ≥20% weight loss with CagriSema, and 34.7% achieved ≥25% weight loss—levels of weight reduction approaching those seen with metabolic surgery.
The combination's effects on glycemic control similarly demonstrate synergy. In the REDEFINE 2 trial involving participants with type 2 diabetes, CagriSema reduced HbA1c by 2.2 percentage points—significantly more than cagrilintide alone (0.9 percentage points) and numerically superior to semaglutide monotherapy (1.8 percentage points). This enhanced glycemic efficacy, combined with greater weight loss, suggests that targeting both GLP-1 and amylin pathways addresses a broader spectrum of metabolic dysfunction than either pathway alone. The complementary mechanisms may also reduce the compensatory responses that limit efficacy of single-pathway interventions: as the body adapts to GLP-1-induced appetite suppression or metabolic changes, concurrent amylin receptor activation maintains therapeutic pressure through alternative mechanisms.
Safety and tolerability profiles indicate that while gastrointestinal adverse events (primarily nausea, vomiting, and constipation) occur more frequently with combination therapy than with either agent alone (72-80% vs 32-40% with monotherapies), these events are predominantly mild to moderate in severity, typically transient, and decrease substantially after the dose titration period. Most participants continue treatment despite initial side effects, suggesting acceptable tolerability relative to the substantial therapeutic benefits achieved. The similar safety profile to component monotherapies, combined with unprecedented efficacy, positions cagrilintide-semaglutide combination therapy as a leading candidate for first-line pharmacological treatment of obesity and obesity-related metabolic diseases.
Sources:
